Clinical trials: Colorectal Malignancy
Cachexia, Non-Small-Cell Lung Cancer
Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia.
Study to assess the safety and tolerability of repeated doses of an investigational new drug in patients with cancer and cachexia.
- Conditions
- Cachexia, Non-Small-Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer
- Trial name
- NCT04299048
- Testing
- PF-06946860
- Where
- 10 sites in United States
- Volunteers
- 11 people
- Sponsor
- Pfizer
Attenuated Familial Adenomatous Polyposis, Familial Adenomatous Polyposis
Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer
This phase II trial studies the side effects of erlotinib hydrochloride and how well it works in reducing duodenal polyp burden in patients with familial adenomatous polyposis at risk of developing colon cancer.
- Trial name
- NCT02961374
- Testing
- Erlotinib, Erlotinib Hydrochloride
- Where
- 8 sites in United States, Puerto Rico
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumors and Hematologic Malignancy
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
This was a study of INCB054329 given to patients with advanced malignancies that were conducted in three treatment groups. Each treatment group had a dose escalation (Part 1) and a dose expansion (Part 3), two of the treatment…
- Trial name
- NCT02431260
- Testing
- INCB054329 Monotherapy
- Where
- 12 sites in United States
- Volunteers
- 69 people
- Sponsor
- Incyte Corporation
Colorectal Cancer
A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients
The purpose of this study is to assess the efficacy and safety of 2 doses of ZACTIMA™ (ZD6474) in combination with FOLFIRI vs FOLFIRI alone for the treatment of colorectal cancer in patients who have failed therapy with an…
- Trial name
- NCT00454116
- Testing
- Vandetanib, FOLFIRI
- Where
- 21 sites in United States, Argentina and 4 more
- Volunteers
- 106 people
- Sponsor
- Genzyme, a Sanofi Company
Chemotherapy-induced Diarrhea
Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea
This study will evaluate the efficacy of Octreotide LAR in preventing chemotherapy-induced diarrhea (with regimens that contain 5 fluorouracil, irinotecan and capecitabine)in patients with colorectal cancer.
- Trial name
- LARCID (NCT00582426)
- Testing
- Octreotide Long Acting Release, Standard Treatment
- Where
- 11 sites in Brazil
- Volunteers
- 139 people
- Sponsor
- Novartis Pharmaceuticals
Minimal Residual Disease, KRAS G12D
A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
This is a Phase 1 study to assess the safety and efficacy of ELI-002 immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of lipid-conjugated peptide-based antigens [Amph-Peptides])…
- Conditions
- Minimal Residual Disease, KRAS G12D, KRAS G12R, NRAS G12D
- Trial name
- AMPLIFY-201 (NCT04853017)
- Testing
- ELI-002 2P
- Where
- 10 sites in United States
- Volunteers
- 25 people
- Sponsor
- Elicio Therapeutics
Colorectal Polyp, Colorectal Adenoma
Standard Colonoscopy Versus Colonoscopy With Endocuff Vision
This study seeks to compare colonoscopy results between a standard method and one using a distal scope attachment (Endocuff Vision).
- Conditions
- Colorectal Polyp, Colorectal Adenoma, Colon Cancer
- Trial name
- NCT03361917
- Testing
- Endocuff Vision
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Indiana University
Rectal Cancer
Biological Mesh Closure of the Pelvic Floor After Extralevator Abdomino Perineal Resection for Rectal Cancer
Rationale: Approximately 800 abdominoperineal resections (APR) are performed for rectal cancer each year in the Netherlands. The extralevator approach (eAPR) reduces the rate of positive margins and improves oncological outcome…
- Trial name
- BIOPEX (NCT01927497)
- Testing
- Biological mesh assisted perineal closure, Primary perineal closure
- Where
- Netherlands
- Volunteers
- 104 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Colorectal Cancer
An Evaluation of a Multi-target Stool DNA (Mt-sDNA) Test, Cologuard, for CRC Screening in Individuals Aged 45-49 and at Average Risk for Development of Colorectal Cancer: Act Now
The primary objective is to confirm the specificity of a multi-target stool DNA test (mt-sDNA), Cologuard, in an average risk population, ages 45-49.
- Trial name
- NCT03728348
- Testing
- mt-sDNA screening test, Colonoscopy
- Where
- 39 sites in United States
- Volunteers
- 983 people, healthy volunteers welcome
- Sponsor
- Exact Sciences Corporation
Colon Cancer
BLI850-302: BLI850 vs an Approved Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy
This is a randomized, parallel, multi-center, single-blind study, comparing BLI850 to an FDA approved bowel preparation in adult subjects undergoing colonoscopy.
- Trial name
- NCT00756548
- Testing
- BLI850, polyethylene glycol 3350 based bowel preparation
- Where
- 12 sites in United States
- Volunteers
- 386 people
- Sponsor
- Braintree Laboratories
Colorectal Neoplasm
Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal Cancer
This trial will evaluate the combination treatment of established chemotherapy regimen mFOLFOX6 with Selinexor, an oral Selective Inhibitor Of Nuclear Export, in patients with metastatic Colorectal Cancer.
- Trial name
- SENTINEL (NCT02384850)
- Testing
- Selinexor, Oxaliplatin, 5-FU
- Where
- 2 sites in Belgium, Germany
- Volunteers
- 10 people
- Sponsor
- GSO Global Clinical Research BV
Colorectal Cancer Metastatic
METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin
This study aims to determine the efficacy, safety, and tolerability of the sequential addition of immune-modulating therapy to standard-of-care therapy of microsatellite-stable (MSS)/mismatch repair-proficient (pMMR) metastatic…
- Trial name
- METIMMOX (NCT03388190)
- Testing
- Nivolumab, FLOX
- Where
- 5 sites in Norway
- Volunteers
- 80 people
- Sponsor
- University Hospital, Akershus
Colorectal Cancer Metastatic, Colorectal Cancer
TheraSphere® For Treatment of Metastases in Liver
To investigate whether the dose predicted by pre-therapy 99mTc MAA SPECT predicts the dose to the liver from the 90Y microspheres as assessed by post-therapy 90Y SPECT/CT or positron emission tomography (PET)/CT.
- Trial name
- NCT04517643
- Testing
- Therasphere Therapy
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Carcinoma
Screening for Prostate Cancer in Older Patients (PLCO Screening Trial)
This clinical trial studies whether screening methods used to diagnose cancer of the prostate, lung, colon, rectum, or ovaries can reduce deaths from these cancers.
- Trial name
- NCT00002540
- Testing
- Laboratory Biomarker Analysis, Medical Examination Assessment, Screening Questionnaire Administration
- Where
- United States
- Volunteers
- 76,685 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Colorectal Cancer
Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer
To estimate the effect of KRAS mutation status (Wild-type versus Mutant) on objective response rate and other measures of efficacy for patients treated with panitumumab in combination with a chemotherapy regimen of irinotecan…
- Trial name
- NCT00508404
- Testing
- Panitumumab, FOLFIRI
- Volunteers
- 154 people
- Sponsor
- Amgen
Colorectal Cancer
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer
This is a Phase II, non-randomized, open-label study to evaluate temozolomide in combination with olaparib in patients with MGMT promoter hypermethylated advanced colorectal cancer.
- Trial name
- NCT04166435
- Testing
- Temozolomide + Olaparib
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Yale University
Colorectal Cancer
First-Line FOLFOX-Bevacizumab for Advanced Colorectal Cancer With Wild-Type Ras
Bevacizumab given at 7.5mg/kg. IV over 10-90 minutes every 3 weeks until disease progression.Panitumumab given at 9mg/kg. IV over 30-90 minutes every 3 weeks until disease progression.Primary Objective: To determine the safety of…
- Trial name
- NCT01057017
- Testing
- intervention
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Brown University
Esophageal Neoplasms, Lung Neoplasms
Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases
Background: Mithramycin is a new cancer drug. In another study, people with chest cancer took the drug 6 hours a day for 7 straight days. Many of them had liver damage as a side effect.
- Conditions
- Esophageal Neoplasms, Lung Neoplasms, Mesothelioma, Thymus Neoplasms
- Trial name
- NCT02859415
- Testing
- Mithramycin
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
Bevacizumab and Capecitabine as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00107315
- Testing
- bevacizumab, capecitabine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Roswell Park Cancer Institute
Rectal Cancer
Induction FOLFOX With or Without Aflibercept Followed by Chemoradiation in High Risk Locally Advanced Rectal Cancer
This trial compares induction treatment with FOLFOX with or without aflibercept in a high risk population selected by MRI, prior to receiving standard chemoradiation (capecitabine combined with 50.4 Gy in 28 days) and surgery, in…
- Trial name
- RIA (NCT02340949)
- Testing
- Aflibercept, 5-Fluoruracil, Oxaliplatin
- Volunteers
- 180 people
- Sponsor
- Grupo Espanol Multidisciplinario del Cancer Digestivo
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.